Using the 21-gene recurrence score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.

Authors

M. Crager

Genomic Health, Redwood City, CA

M. Crager , G. Tang , S. Shak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen.

First Author: Norman Wolmark

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A comparative analysis of distant recurrence risk assessments by Oncotype DX recurrence score alone and integrated with clinicopathologic factors in early-stage breast cancer.

First Author: Ciara Marie Kelly

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.

First Author: Yi Zhang

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.

First Author: Christopher David Walden